Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Eberelbin, Navelbine, Navin, Vinocleus, Vinorelbin; Belgium: Navelbine, Vinorelbin; Bulgaria: Navelbin, Vinorelbin; Cyprus: Navelbine; Czech Republic: Navelbine, Navirel, Nibrevin, Vinorelbine; Denmark: Navelbine, Navirel, Vinorelbin; Estonia: Navelbine, Vinorelbine; Finland: Navelbine, Navirel, Vinorelbin; France: Navelbine, Vinorelbine; Germany: Bendarelbin, Eurovinorelbin, Navelbine, Navin, Riborelbin, Vinorelbin; Greece: Eunades, Navelbine, Vinorelbine; Hungary: Navelbine, Vinorelbin, Visera; Ireland: Navelbine, Vinorelbine; Italy: Navelbine; Latvia: Navelbine, Vinorelbine; Lithuania: Navelbine, Vinorelbine; Luxembourg: Navelbine; Netherlands: Navelbine, Vinorelbine; Poland: Navelbine, Navirel, Neocitec, Vinorayne, Vinorelbine, Vinorelsin; Romania: Navelbine, Telbine, Vinorelbin; Slovakia: Navelbine, Navirel, Vinorelbine; Slovenia: Navelbine, Vinorelbin; Spain: Navelbine, Vinorelbina; Sweden: Navelbine, Navirel, Relbinalur, Vinobur, Vinorelbine; UK: Navelbine, Vinorelbine.

North America

Canada: Navelbine, Vinorelbine; USA: Navelbine, Vinorelbin.

Latin America

Argentina: Filcrín, Navelbine, Neocitec, Sulcoline, Vilne, Vinarine, Vinkebir, Vinorel, Vinorelbina, Vinorelbine, Vinorgén; Brazil: Navelbine, Neocitec, Norelbin; Mexico: Bagovir, Navelbine, Navildez, Viessia, Vinilex.


Japan: Navelbine.

Drug combinations

Vinorelbine and Cisplatin

Vinorelbine and Gemcitabine

Vinorelbine and Trastuzumab

Vinorelbine, Cetuximab, and Cisplatin


Vinorelbine Tartrate: C~45~H~54~N~4~O~8~ 2C~4~H~6~O~6~. Mw: 1079.11. (1) C’-Norvincaleukoblastine, 3′,4′-didehydro-4′-deoxy-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:2); (2) 3′,4′-Didehydro-4′-deoxy-8′-norvincaleukoblastine L-(+)-tartrate (1:2). CAS-125317-39-7; CAS-71486-22-1 (vinorelbine)(1993).

Pharmacologic Category

Antineoplastic Agents; Plant Alkaloids and Other Natural Products. Vinca Alkaloid. (ATC-Code: L01CA04).

Mechanism of action

Binds to tubulin and inhibits microtubule formation, therefore arresting cell at metaphase by disrupting formation of mitotic spindle. Vinorelbine may also interfere with nucleic acid and protein synthesis by blocking glutamic acid utilization.

Therapeutic use

Treatment of non-small cell lung cancer.

Pregnancy and lactiation implications

Animal studies demonstrated embryotoxicity, fetotoxicity, decreased fetal weight, and delayed ossification. There are no adequate, well-controlled studies in pregnant women. Not recommended in nursing women.

Unlabeled use

Treatment of breast cancer, cervical cancer, and ovarian cancer.


Pre-treatment granulocyte counts <1000/mm^3^.

Warnings and precautions

Hazardous agent. Bone marrow suppression (severe granulocytopenia). May cause severe constipation, paralytic ileus, intestinal obstruction, necrosis, and/or perforation. May cause new onset or worsening of pre-existing neuropathy. Fatal cases of interstitial pulmonary changes and acute respiratory distress syndrome reported. Use with caution in hepatic impairment, and in neurotoxicity. May have radiosensitizing effects with prior or concurrent radiation therapy. Higher incidence of granulocytopenia when given in combination with cisplatin. Acute shortness of breath and severe bronchospasm reported rarely (usually associated with concurrent administration of mitomycin). Avoid extravasation (infiltration may cause irritation, thrombophlebitis and/or local tissue necrosis). Not for intrathecal use (may result in death). For I.V. use only.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart